Bayer Aktiengesellschaft

Other

Bayer Aktiengeselischaft

Rolf Henning

Graham Sturton

Johannes-Peter Stasch

Mazen Es-Sayed

Michael Sperzel

Mary F Fitzgerald

Karl-Heinz Schlemmer

Andreas Knorr

Wolfgang Bender

Ulrich Nielsch

Gabriele Br&auml;unlich

R&uuml;diger Fischer

Elisabeth Perzborn

Ulrich Rosentreter

Klaus Dembowsky

Walter Hübsch

Andrea Vaupel

Thomas Krahn

Marcus Bauser

Trevor S Abram

Thomas Krämer

Burkhard Fugmann

Gunter Benz

Stephan Schneider

Stephen Richard Tudhope

Rudiger Fischer

Arnel B Concepcion

Barbara Briggs

Bernd Riedl

Helmut Haning

William H Bullock

Kevin Nash

Gabriele Braunlich

Burkhardt Fugmann

Gabriele Br{umlaut Over (a)}unlich

Olga Salcher-Schraufstatter

Olga Salcher-Schraufstätter

Philip J Gardiner

Günter Benz

Lorenz Mayr

The invention relates to compounds of general formula (I), a method for the production thereof and the use thereof as pharmacologically effective substances for a broad medical indication spectrum. Furthermore, selective adenosine receptor ligands, preferably selective adenosine A1-, adenosine A2a- and/or adenosine A2b-receptor ligands are provided for the prophylaxis and/or the treatment of diseases, especially cardiovascular diseases, diseases of the urogenital region, diseases of the respiratory tract, inflammatory and neuroinflammatory diseases, diabetes, especially pancreatic diabetes, neurodegenerative diseases, pain states, cancer as well as liver fibrosis and liver cirrhosis.

Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use

This application relates to compounds of formula (I), 

Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof

Novel 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives, use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives as Matrix Metalloprotease Inhibitors for the Treatment of Respiratory Diseases, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (I) (T)A&#x2014;B&#x2014;D&#x2014;E&#x2014;COH wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group, x is 0, 1, or 2; the group D represents (a), (b), (c), or (d); the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.

Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases

N-(3-benzofuranyl)urea-derivatives are prepared by reacting of 3-amino-substituted benzofuranes with appropriate substituted isocyanates or isothiocyanates. The N(3-benzofuranyl)urea-derivatives can be used as active ingredients in medicaments particularly for the treatment of acute and chronic inflammatory processes.

N-(3-benzofuranyl)urea-derivatives

Benzofuranylsulfonates

N-(3-benzofuranyl) urea-derivatives

3-Urea-pyridofurans and -pyridothiophenes are prepared by reacting appropriately substituted 3-amino-pyridofurans or -pyridothiophenes with isocyanates or isothiocyanates. The 3-urea-pyridofurans and -pyridothiophenes can be used as active ingredients in medicaments, particularly in medicaments for the treatment of acute and chronic inflammatory processes.

3-Ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes

Heterocyclyclcarbonyl substituted benzofuranyl-ureas are prepared by reacting heterocyclylcarbonyl substituted 3-amino-benzofuranes with appropriate isocyanates or isothiocyanates. The unsubstituted ureas are transferred into substituted ureas by usual methods of substitution. The heterocyclylcarbonyl substituted benzofuranyl-ureas are useful as active ingredients in medicaments particularly for the treatment of acute and chronical inflammatory processes.

Heterocyclylcarbonyl substituted benzofuranyl-ureas

Renin-inhibiting aminomethyl peptides of the formula ##STR1## in which A is H, an alkyl radical, a sulphony radical or an amino-protecting group,

Aminomethyl peptides

Renin-inhibiting aminomethyl peptides of the formula ##STR1## in which A is H, an alkyl radical, a sulphonyl radical or an amino-protecting group,

Renin-inhibiting peptides having an aminomethyl side chain

Anti-hypertensive compounds of the formula ##STR1## in which A represents hydrogen, C.sub.1 -C.sub.8 -alkyl, C.sub.7 -C.sub.14 -aralkyl, phenylsulphonyl, tolylsulphonyl or C.sub.1 -C.sub.8 -alkylsulfphonyl, or represents an aminoprotective group,

Renin inhibitors and aminoacid and aminoaldehyde derivatives

Growing community of inventors

Wuppertal, Germany

Rolf Henning